Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (111-120 of 302) with videos related to

Pageof 31
Sort By:
Breast (Edinburgh, Scotland)|October 19, 2006
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II studyMario Campone, Pierre Fumoleau, Patrice Viens, et al.
Drug Safety|June 29, 2020
Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on HepatotoxicityJames H Lewis, Paul H Cottu, Martin Lehr, et al.
International Journal of Oncology|March 27, 2012
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomasDelphine Loussouarn, Anne-Gaëlle Le Loupp, Jean-Sébastien Frenel, et al.
International Journal of Public Health|December 18, 2025
Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study)Pauline Petit, Myriam Blanchin, Frederic Bigot, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Deep learning approaches for bone and bone lesion segmentation on 18FDG PET/CT imaging in the context of metastatic breast cancer<sup>.</sup>Noemie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational studyGilles Freyer, Mario Campone, Julien Peron, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
Journal of Neuro-Oncology|June 28, 2011
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesNancy U Lin, Wolfgang Eierman, Richard Greil, et al.
Future Oncology (London, England)|August 12, 2015
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trialSéverine Guiu, Céline Charon-Barra, Déwi Vernerey, et al.
Therapeutic Advances in Medical Oncology|October 1, 2025
Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomesLaurent Mathiot, Olivier Kerdraon, Florent Le Borgne, et al.
Pageof 31

Showing results (111-120 of 302) with videos related to

Sort By:
Pageof 31
Breast (Edinburgh, Scotland)|October 19, 2006
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II studyMario Campone, Pierre Fumoleau, Patrice Viens, et al.
Drug Safety|June 29, 2020
Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on HepatotoxicityJames H Lewis, Paul H Cottu, Martin Lehr, et al.
International Journal of Oncology|March 27, 2012
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomasDelphine Loussouarn, Anne-Gaëlle Le Loupp, Jean-Sébastien Frenel, et al.
International Journal of Public Health|December 18, 2025
Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study)Pauline Petit, Myriam Blanchin, Frederic Bigot, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Deep learning approaches for bone and bone lesion segmentation on 18FDG PET/CT imaging in the context of metastatic breast cancer<sup>.</sup>Noemie Moreau, Caroline Rousseau, Constance Fourcade, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational studyGilles Freyer, Mario Campone, Julien Peron, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
Journal of Neuro-Oncology|June 28, 2011
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesNancy U Lin, Wolfgang Eierman, Richard Greil, et al.
Future Oncology (London, England)|August 12, 2015
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trialSéverine Guiu, Céline Charon-Barra, Déwi Vernerey, et al.
Therapeutic Advances in Medical Oncology|October 1, 2025
Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomesLaurent Mathiot, Olivier Kerdraon, Florent Le Borgne, et al.
Pageof 31